Latest Filings

Issuer Activity

Overview :: ACADIA Pharmaceuticals Inc. (OQ:ACAD) [?]
Business Focus: Biotechnology & Medical Research Share on StockTwits
Recent Price for ACAD
USD 38.270 +0.300 (+0.790%)
NSQ Delayed 15 minutes
09:49 EST
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
38.500 38.480 N/A 232,527 3,818.21
1-Day Low 52-Week Low Yield Avg. Volume  
38.050 15.640 0.0% NSQ  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for ACAD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 10:04am ET March 2nd, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -10,000  
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -7,067  
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -2,780  
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Common Stock S - Open market or private sale -19,847 $35.05
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 10,000 $1.36
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 7,067 $8.49
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 2,780 $8.49
Feb 19/15 Feb 17/15 Hacksell Uli Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -30,000  
Feb 19/15 Feb 17/15 Hacksell Uli Indirect Ownership Common Stock S - Open market or private sale -30,000 $34.30
Feb 19/15 Feb 17/15 Hacksell Uli Indirect Ownership Common Stock G - Gift 30,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for ACAD within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 10:04am ET March 2nd, 2015
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -10,000  
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -7,067  
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Stock option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -2,780  
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Common Stock S - Open market or private sale -19,847 $35.05
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 10,000 $1.36
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 7,067 $8.49
Feb 19/15 Feb 17/15 Rasmussen Torsten Indirect Ownership Common Stock M - Exercise or conversion exempt under rule 16b-3 2,780 $8.49
Feb 19/15 Feb 17/15 Hacksell Uli Direct Ownership Stock Option (right to buy) M - Exercise or conversion exempt under rule 16b-3 -30,000  
Feb 19/15 Feb 17/15 Hacksell Uli Indirect Ownership Common Stock S - Open market or private sale -30,000 $34.30
Feb 19/15 Feb 17/15 Hacksell Uli Indirect Ownership Common Stock G - Gift 30,000  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Key People
Leslie L. Iversen
Independent Chairman of the Board
Uli Hacksell
President, Chief Executive Officer, Director
Stephen R. Davis
Executive Vice President, Chief Financial Officer and Chief Business Officer
Roger G. Mills
Executive Vice President - Development, Chief Medical Officer
Terrence O. Moore
Executive Vice President, Chief Commercial Officer
Glenn F. Baity
Vice President, General Counsel, Secretary
Company Contact
Address: SUITE 100, 11085 TORREYANA ROAD
SAN DIEGO CA 92121
Tel: N/A
Website: www.acadia-pharm.com
IR: See website
Business Overview
ACADIA Pharmaceuticals Inc. (ACAD) is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in neurological and related central nervous system disorders. It has a pipeline of product candidates led by NUPLAZID (pimavanserin), which is in Phase III development as a treatment for Parkinson's disease psychosis.
Financial Overview
For the nine months ended 30 September 2014, ACADIA Pharmaceuticals Inc. revenues decreased 93% to $73K. Net loss increased from $25.9M to $64.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Other Research and development increase from $17.4M to $39M (expense), Stock-Based Compensation in SGA increase from $2.1M to $5.8M (expense).
Employees: 48 as of Dec 31, 2013
Reporting Currency: U.S. Dollars
Enterprise value: $3,466M as of Dec 31, 2014
Annual revenue (TTM): $0.11M as of Dec 31, 2014
EBITDA (TTM): -$76.66M as of Dec 31, 2014
Net annual income (TTM): -$76.16M as of Dec 31, 2014
Free cash flow (TTM): -$59.11M as of Dec 31, 2014
Net Debt Last Fiscal Year: N/A
Shares outstanding: 99,770,300 as of Oct 31, 2014
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Quintiles Transnational H (N:Q)
Seattle Genetics (OQ:SGEN)
Synageva Biopharma (OQ:GEVA)